On August 5, Novo-Nordisk A/S rose 3.55% in regular trading, trading at $48.22/share, with turnover of $285 million. The stock gained momentum ahead of its Q2 earnings report scheduled for pre-market release the same day, with consensus EPS expected at $0.81.

Multiple positive developments underpinned the rally. The company recently partnered with H1 to advance AI-driven clinical development at scale. Oral Wegovy demand in the US has exceeded expectations since launch, while the Wegovy tablet (semaglutide 25mg) secured EU Commission approval for obesity treatment. Additionally, India's drug regulator approved Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), with Phase 3 data showing steatohepatitis resolution in 63% of patients.

The rebound follows a nearly 10% decline triggered by the failure of its cardiovascular drug ziltivekimab in a Phase 3 trial on July 31. The current recovery suggests the market is re-pricing the resilience of Novo-Nordisk A/S's core GLP-1 franchise amid intensifying competition with Eli Lilly in the obesity drug market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)